BioSpace News Archive

José (Joe) E. Almeida, Baxter’s chairman and chief executive officer, is scheduled to present on Monday, January 13, 2020 at 10:00 a.m. Pacific Time.

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, announced that it has commenced an underwritten public offering of shares of its common stock.

The presentation will be webcast. Links to the live and archived webcast will be available on Veeva’s investor relations website at ir.veeva.com

Research and real-world evidence support the use across a range of leukemias and lymphomas and demonstrate utility in multiple tissue types, including blood and bone marrow Late breaker presentation of CANDOR study includes secondary endpoint of improved NGS MRD negative Complete Response Rate at 12 months

Exact Sciences Corp. announced Dr. David Ahlquist, co-inventor of Cologuard® and emeritus professor of medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, has been named a Fellow of the National Academy of Inventors.

Update adds over 100 new tumor models and 150 new bioinformatic data sets, increasing translational power of the Compendium

Trial of Voclosporin Meets All Primary and Secondary Endpoints with Clean Safety Profile

Published data from a second robust Phase 3 clinical trial demonstrated efficacy, safety and tolerability of ubrogepant, an orally-administered CGRP receptor antagonist

Renowned STEM Education Leader, Committed to Building Access, Joins as Museum Inaugurates a Decade of Growth

Highlights of the presentation, entitled “Interaction of ALS Progression and the Efficacy of MN‑166”, which will be presented by Kazuko Matsuda, M.D. Ph.D. M.P.H., Chief Medical Officer of MediciNova, Inc.